natgillin/translations-raw huggingface dataset:
A neutralising antibody which binds human IL-17A and human IL-17F according to claim 1 which cross-blocks the binding of an antibody comprising the heavy chain sequence given in SEQ ID NO:9 and the light chain sequence given in SEQ ID NO:7 to human IL-17A and human IL-17F and which inhibits the binding of an antibody comprising the heavy chain sequence given in SEQ ID NO:9 and the light chain sequence given in SEQ ID NO:7 to human IL-17A and human IL-17F by greater than 80% using competition ELISA or surface plasmon resonance. 
Antitijelo prema zahtjevu 1, pri čemu antitijelo obuhvaća teški lanac koji obuhvaća varijabilno područje teškog lanca koji se sastoji iz sekvence aminokiselina koja je prikazana u SEQ ID NO: 16 i konstantno područje teškog lanca koji je konstantno područje humanog gama-1 teškog lanca, i laki lanac koji obuhvaća varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NOS: 19 i konstantnog područja lakog lanca koji je konstantno područje humanog kapa lakog lanca.
The assembly 12 is closed in a downward region by an insole 16, which, in this embodiment, is perforated but can be made of breathable material. 
Sklop 12 je u donjem dijelu zatvoren unutarnjim potplatom 16, koji je u ovom utjelovljenju perforiran, ali može biti izrađen od prozračnog materijala.
A DNA detection kit comprising: at least one DNA molecule of sufficient length of contiguous nucleotides of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or the complement thereof, to function as a DNA primer or probe specific for corn event MON89034 and/or its progeny. 
Detekcijski DNA kit sadrži: minimalno jednu DNA molekulu koja se sastoji od najmanje 18 u nizu poredanih nukleotida homolognih ili komplementarnih SEQ ID NO: 3, SEQ ID NO: 4, ili SEQ ID NO: 5, da funkcionira kao DNA začetnica ili proba za biljku kukuruza oznake MON&89034 1 / ili njenih potomaka.
A drug delivery system according to claim 1, characterized in that said pharmaceutically active substance has a solubility per se in water of at least 4 mg/ml, and that said complex is a non-covalent complex having a solubility in water of below 0.1 mg/ml. 
Sustav dostave lijeka prema zahtjevu 1, naznačen time da spomenuta farmaceutski aktivna tvar ima topljivost per se u vodi od barem 4 mg/ml, te time da je spomenuti kompleks ne-kovalentni kompleks koji ima topljivost u vodi manje od 0,1 mg/ml.
Compounds of the formula (II) can be prepared by reduction of tetrabenazine to give a dihydrotetrabenazine followed by dehydration of the dihydrotetrabenazine. 
Spojevi formule (II) se mogu pripremiti redukcijom tetrabenazina dajući dihidrtetrabenazin nakon čega slijedi dehidriranje dihidrotetrabenazina.
The method of claim 1, wherein the step a) of estimating the compression quality impact IcodA uses one or more coefficients or the bit rate or one or more coefficients and the bit rate, wherein the one or more coefficients depend on the type of the encoded audio signal, or encrypted audio signal, or encoded and encrypted audio signal. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se u koraku a) procjene utjecaja kompresije na kvalitetu Zcod, upotrebljava jedan ili više koeficijenata ili brzina bita ili jedan ili više koeficijenata i brzina bita, gdje jedan ili više koeficijenata ovise o tipu kodiranog audio signala, ili enkriptiranog audio signala, ili kodiranog i enkriptiranog audio signala.
a pH control system for adjusting pH level of the mixture. The apparatus according to claim 15, wherein the temperature control system includes heating oil encapsulating at least a portion of the perimeter of the chamber. 
Uređaj prema patentnom zahtjevu 10, naznačen time, da sredstvo za reguliranje temperature sadrži grijaće ulje koje u zatvorenom kućištu opkoljava najmanje jedan dio opsega komore.
The center-tap is connected to the terminal of a very low value resistor 111a (a few ohm) to which, at the other terminal, are connected the anodes of two diodes 310, 311 whose cathodes are connected to the terminals of the secondary winding of transformer 300. 
Klizač je spojen na priključak otpornika vrlo niske vrijednosti 111a (nekoliko ohma), na koji, na drugi priključak su spojene anode dviju dioda 310,311, čije su katode spojene na priključke sekundarnog transformatora 300.
Recrystallization of the escitalopram oxalate salt: 
Broj objave europskog patenta:
Compounds according to Claim 1-6 and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment of cancer, septic shock, Primary open Angle Glaucoma (POAG), hyperplasia, rheumatoid arthritis, psoriasis, artherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation, and/or neurodegenerative diseases. 
Spojevi prema zahtjevu 1-6 i njihove farmaceutski upotrebljive soli, tautomeri 1 stereoizomeri, uključujući njihove smjese u svim omjerima, naznačeni time da su za upotrebu u liječenju raka, septičkog šoka, primarnog glaukoma otvorenog kuta (POAG), hiperplazije, reumatoidnog artritisa, psorijaze, arteroskleroze, retinopatije, osteoartritisa, endometrioze, kronične upale, i/ili neurodegenerativnih bolesti.
wherein the VL domain is humanised; or 
VL-domena je humanizirana; ili
In one embodiment the container is provided with an accommodating cavity with a replaceable container containing CO2 under a pressure higher than 1 bar therein. 
U jednoj izvedbi, spremnik ima odgovarajući utor u kojem se nalazi zamjenjivi spremnik koji sadrži CO; pod pritiskom većim od 1 bar.
{wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, 
Y' predstavlja atom dušika ili skupinu predstavljenu sa CR", Y* predstavlja atom dušika ili skupinu predstavljenu sa CR", vi PERI atom dušika ili skupinu predstavljenu sa CR",
The titre of the Reference Material was calculated in each assay as follows: EPMATHMARKEREP 
Titar Referentnog Materijala bio je izračunat za svaki test kako slijedi:
The method according to claim 1, wherein the individual is suffering from sepsis, ALI/ARDS, preeclampsia, no reflow stenosis, pulmonary edema, post-radiation pulmonary edema, or post-endarteriectomy pulmonary edema. A method for inhibiting endothelial barrier dysfunction in a collection of endothelial cells comprising an endothelial barrier that dysfunctions or is at risk of dysfunction, said method comprising: 
Inhibitor za uporabu sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time što navedeni pojedinac koji boluje od ili je u opasnosti oboliti od upalnog edema boluje od sepse, ALI/ARDS, preeklampsije, stenoze bez ponovnog protoka, plućnog edema i poželjno nakon zračenja plućnog edema ili plućnog edema poslije endarterektomije.
The method of claim 15, wherein tipifarnib is administered for at least 3 cycles. The method of claim 15, wherein tipifarnib is administered for at least 6 cycles. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, pri čemu je tipifarnib primjenjivan barem 3 ciklusa ili barem 6 ciklusa.
Compounds of formula I have an inhibitory effect on one or more enzymes which utilize folic acid, and in particular metabolic derivatives of folic acid as a substrate. 
Spojevi formule I imaju inhibitorski učinak na jedan ili više enzima koji kao supstrate koriste folnu kiselinu, i posebno metaboličke supstrate folne kiseline.
is NO2, CN or SO2R′; is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; and X1′ are each independently CH or N, with the proviso that X1 and X1′ are not simultaneously CH; 
R* je vodik, halogen, C;-C; alkil ili C,-C, alkil supstituiran halogenom; XLX1 suCHili N, uz uvjet da X1/X1? nisu istodobno CH; nje0,1ili2; i farmaceutski aktivne soli uz dodatak kiseline.
Accordingly, in a first aspect the present invention provides a kit comprising separately an agent capable of activating CD4+CD25+ regulatory T cells and methotrexate, wherein the agent is a humanized anti-CD4 antibody which comprises an H chain V domain and an L chain V domain, and wherein: (a) the H chain V domain comprises the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and the L chain V domain comprises the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; and/or (b) the H chain V domain has at least 80% sequence identity with SEQ ID No: 1 and the L chain V domain has at least 80% sequence identity with SEQ ID No: 2. The present inventors have unexpectedly found that a combination of an agent capable of activating CD4+CD25+ regulatory T cells with methotrexate has a therapeutic effect, and is surprisingly advantageous in relation to the reduced number of antibody-related side effects. 
(b) V domena lanca H ima identičnost slijeda od najmanje 80% sa SEQ ID NO: 1, a V domena lanca IL ima identičnost slijeda od najmanje 80% sa SEQ ID NO: 2. Komplet u skladu s patentnim zahtjevom 1, naznačen time što humanizirano protutijelo protiv CD4 sadrži V domenu lanca H, koju definira SEQ ID NO: 1, 1 V domenu lanca L, koju definira SEQ ID NO: 2. Sredstvo koje može aktivirati regulacijske T-stanice CD4+CD25+ i metotreksat u obliku kombiniranog pripravka za istodobnu, odvojenu ili uzastopnu upotrebu u medicini, naznačen time što je sredstvo humanizirano protutijelo protiv CD4 koje sadrži V domenu lanca H i V domenu lanca L, te što:
As the active ingredient of the medicament of the present invention, two or more of the aforementioned substances may be used in combination. 
Kao aktivni sastojak lijeka prema ovom izumu mogu se upotrijebiti dvije ili više od gore navedenih tvari, u kombinaciji.
A liver organoid according to any one of claims 11 to 14, which comprises a cystic structure and on the outside, a layer of cells with at least one bud and a central lumen. 
Organoid jetre prema zahtjevu 9, koji obuhvaća cističnu strukturu i izvana, sloj stanica sa najmanje jednom kvržicom i centralnim lumenom.
The present invention thus provides dihydrospiro-[cycloalkylamine]-pyrimidone (or pyrimidinone) derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof: 
Prema tome, ovaj izum osigurava dihidrospiro[cikloalkilamin|pirimidonske derivate, prikazane formulom (1), ili njihove soli, njihove solvate ili hidrate: R1
The formulation of claim 10 or 11, wherein the first pharmaceutically acceptable excipient component or the second pharmaceutically acceptable excipient component includes at least one of a binder, a diluent, a stabilizing agent, a disintegrant, an anti-foaming agent or an anti-adherent; or wherein the first pharmaceutically acceptable excipient component includes a first amount of a diluent, and the second pharmaceutically acceptable excipient component includes a second amount of the same diluent so that the diluent in the formulation is evenly divided between the intra-granular fraction and the extra-granular fraction, optionally, wherein the diluent is selected from one or a combination of lactose monohydrate, microcrystalline cellulose or sorbitol. 
Formulacija iz zahtjeva 10. ili 11., pri čemu prva farmaceutski prihvatljiva komponenta pomoćne tvari ili druga farmaceutski prihvatljiva komponenta pomoćne tvari uključuje barem jedno od vezivnog sredstva, razrjeđivača, stabilizatora, sredstva za raspadanje, sredstva protiv pjenjenja ili sredstva protiv prianjanja; ili pri čemu prva farmaceutski prihvatljiva komponenta pomoćne tvari uključujuće prvu količinu razrjeđivača, a druga farmaceutski prihvatljiva komponenta pomoćne tvari uključuje drugu količinu istoga razrjeđivača tako da je razrjeđivač u formulaciji ravnomjerno raspodijeljen između intragranularne frakcije i ekstragranularne frakcije, neobavezno, pri čemu se razrjeđivač bira iz jedne ili kombinacije laktoze monohidrata, mikrokristalične celuloze ili sorbitola.
The method in accordance with claim 1, further comprising totally or partly removing the matrix from the layer after c). 
Postupak u skladu s patentnim zahtjevom 1 i bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se matricu posve ili djelomično uklanja iz sloja nakon koraka d.
The drippable ophthalmic gel according to claim 1 characterized in that the amount of polyacrylate is in the range of > 0.2 % to 3.0 % by weight, preferably in the range of > 0.2 % to 0.7 % by weight. 
Bimatoprost oftalmološki gel u obliku kapi temeljem zahtjeva 1, naznačen time da je količina poliakrilata u rasponu od > 0,2 % do 3,0 % masenog udjela, poželjno u rasponu od > 0,2 % do 0,7 % masenog udjela.
The lyophilised anti-tumor composition according to claim 12, wherein said vial contains a composition comprising: about 0.25 mg ET-743, about 100 mg sucrose, and about 6.8 mg potassium dihydrogen phosphate. 
Liofilizirani oblik prema patentnom zahtjevu 14, naznačen time što navedena ampula sadrži smjesu koja sadrži: oko 0.25 mg ET-743, oko 100 mg saharoze i oko 6.8 mg fosfata, pri čemu se navedenih 6.8 mg fosfata računa kao kalij dihidrogen fosfat.
iii) the tablet thickness to tablet weight ratio is from 0.002 to 0.06 mm/mg. 
Direktno komprimirana farmaceutska tableta prema zahtjevu 1, naznačena time, da odnos debljine tablete prema masi tablete iznosi od 0,002 do 0,06 mm/mg.
A pharmaceutical composition comprising a therapeutically effective amount of a combination as claimed in any one of claims 1-3 wherein the composition is for oral administration. 
Farmaceuiski sastav koji sadrži terapeutski učinkovitu količinu kombinacije prema bilo kojem zahtjevu 1-3, naznačen time, da se spomenuti sastav daje oralno.
The communication apparatus of claim 5, further adapted to: monitor the client interface for any communication from the remote computer; and discontinue operating the client interface and the EDR interface in the pass-through mode if the remote computer is not active at the client interface. 
Komunikacijski uređaj sukladno zahtjevu 5, naznačen time, da je nadalje prilagođen: pratiti sučelje korisnika svaku komunikaciju s udaljenog računala; i prekida rad sučelja korisnika i EDR sučelja u prolaznom modu ako udaljeno računalo nije aktivno na korisničkom sučelju.
The use of a compound of formula (I) as defined in any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which antagonism of the CX3CR1 receptor is beneficial. 
Upotreba spoja formule (T) kako je definirano u bilo kojem zahtjevu 1 do 10, ili njegove farmaceutski prihvatljive soli, naznačena time, da se navedeni spoj upotrebljava kod proizvodnje lijeka za liječenje ili profilaksu humanih bolesti ili stanja u kojima se koristi antagonizam CX3CRI receptora.
Preferably, the grooves extend along the entire length of the hinges so that the protrusions 80 may extend along the entire length of the edge of the outer parts and/or metal layer/part which reinforces said parts. 
Poželjno je da se utori prostiru duž cijele dužine panta, tako da se izbočenja 80 mogu protezati duž cijele dužine ruba vanjskih dijelova i/ili metalnog sloja/dijela koji pojačava navedene dijelove.
An object of the present invention is a method of treating onychomycosis in a patient in need of such a treatment, comprising applying to the affected areas of said patient a composition comprising at least about 9% by weight terbinafine or a pharmaceutically acceptable salt thereof, hydroxypropyl chitosan, a lower alkanol and water, once weekly. 
HR P20191243T1 PATENTNI ZAHTJEVI nos Pripravak koji sadrži najmanje oko 9 % masenog udjela terbinafina ili njegove farmaceutski prihvatljive soli, hidroksipropil hitozan, niži alkanol 1 vodu za primjenu u liječenju onihomikoze kod pacijenta, naznačen time, što se spomenuti pripravak nanosi na pogođena područja pacijenta jednom tjedno.
The pharmaceutical composition for use according to any one of claims 27-29, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 27-29, naznačen time da je stanje kožna bolest ili poremećaj, sepsa, dermatitis, osteoartritis, rak, upala, autoimuna bolest, upalna bolest crijeva, komplikacija od lokaliziranog izlaganja ili izlaganja cijelog tijela ionizirajućem zračenju, mukozitis, akutno ili kronično zatajenje organa, bolest jetre, pankreatitis, poremećaj očiju, plućna bolest, ili dijabetes.
A wet granulated pharmaceutical composition of Candesartan cilexetil and/or its solvates or hydrates, comprising: 
Vlažno granulirani farmaceutski pripravak kandesartan-cileksetila i/ili njegovih solvata ili hidrata, naznačen time
A pharmaceutical composition comprising a compound of claims 1 and 2 - 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 24, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivi nosač.
The 11 th item relates to a floor panel according to the 10th item, characterized in that the tensioning system (48) consists of a cam realized at said extremity, which cam, when the lock-up body (14) is rotated outward, also subjects this lock-up body (14) to an axial displacement in the direction of the locking portion (17). 
Podni panel sukladno zahtjevu 10, naznačen time što se zatezni sustav (48) sastoji od zubaca na navedenom ekstremitetu, koji zupci, kada je tijelo za zaključavanje (14) rotirano prema van, također podvrgavaju tijelo za zaključavanje (14) aksijalnom izmještanju u smjeru dijela za zaključavanje (17).
The method of claim 2, wherein the adjuvant is selected from D-mannose, sucrose, glucose, calcium phosphate, a dendrimer, an oligonucleotide, high molecular weight hyaluronic acid, and a lipid. 
Sastav za uporabu prema zahtjevu 2, naznačen time, da se pomoćno sredstvo odabire od sljedećih: D-manoza, saharoza, glukoza, kalcijev fosfat, dendrimeri, oligonukleotidi, hijaluronska kiselina velike molekularne mase, ili liposomi.
An immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, for use in a method for immunizing a subject against influenza virus comprising steps of (i) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and later (ii) administering to the subject the immunogenic composition comprising hemagglutinin antigen from the second clade of H5 influenza A virus, wherein the first and second clades are different, and wherein: 
Imunogeni pripravak koji sadrži antigen hemaglutinina iz drugog klada H5 virusa influenco A, naznačen time da je za uporabu u postupku imunizacije subjekta protiv virusa influence koji sadrži korake (i) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, te zatim (11) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz drugog klada H5 virusa influence A, pri čemu su prvi i drugi klad međusobno različiti, te gdje:
According to some embodiments, the outward facing edge of the foamed plastic strips, i.e. the edge facing the side edge of the plastic film sheet, has a wavelike profile to prevent bulking of the foamed plastic strips when the protective wrapping is wrapped around the edges of the cylindrical object. 
Zaštitni omotač (200) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prema van okrenuti rub pjenastih plastičnih vrpci ima valoviti profil (208a, 208b) kako bi se sprječilo nabreknuće pjenastih plastičnih vrpci kada je zaštitni omotač namotan oko rubova valjkastog objekta.
A glucorticoid contained in a delayed-release dosage form for use according to claim 3, wherein the increased Interleukin 6 levels are caused by a rheumatic disease, e.g. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema patentnom zahtjevu 3, pri čemu su povišene razine interleukina 6 uzrokovane reumatskom bolesti, npr.
The ocean-going workboat of claim 6, wherein the total length of the boat is smaller than 65 meter and is larger than 10 meter. 
Oceanski radni brod prema zahtjevu 6, naznačen time što je ukupna duljina broda manja od 65 metara 1 veća od 10 metara.
R2c represents a hydrogen atom, a fluorine atom, a chlorine atom, methyl, monofluoromethyl, difluoromethyl or trifluoromethyl, or a pharmaceutically acceptable salt thereof. 
R*" predstavlja atom vodika, atom fluora, atom klora, metil, monofluorometil, difluorometil ili trifluorometil, ili prolijek, ili farmaceutski prihvatljiva sol.
Still more advantages compounds have an EC50 value in this assay of less than about 1 uM. 
Još je povoljnije kad spojevi izuma imaju EC5g vrijednost u tim ispitivanjima manjuod oko 1uM.
Method according to any of the claims 17 to 18 wherein, if the temperature inside the tunnel is minor that the pre-established temperature of control, an alarm is activated (18) and there is cut the dosing of tin tetrachloride anhydrous. 
Metoda prema bilo kojem od patentnih zahtjeva 17 do 18 gdje, ako je temperatura unutar tunela niža od prethodno utvrđene temperature kontrole, alarm (18) se aktivira 1 prekida se doziranje bezvodnog kositar tetraklorida.
performing a curd and whey separation, wherein a cheese alternative product is obtained, which contains ≥ 5 (w/w) % fat, preferably about 5 to 30 (w/w) % fat, more preferably about 5 to 25 (w/w) % fat and most preferably about 5 to 20 (w/w) % fat. 
razdvajanje skute i sirutke, čime se dobiva zamjenski sirni proizvod koji sadrži > 5 (w/w) % masti, poželjno je 5 do 30 (w/w) % masti, poželjnije je 5 do 25 (w/w) % masti, a najpoželjnije je 5 do 20 (w/w) % masti.
The compound of claim 1 or a salt or polymorph thereof, wherein R3 is -C(O)-NH-Z3(R10); X3 is absent or lower alkylidene; Z3 is absent, -SO3 or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy or carbonylalkoxy); and, R10 is hydrogen, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl is each optionally substituted by one or more hydroxy, halogen, alkyl (optionally substituted at one or more positions by halogen), alkoxy, carboxy, carbonylalkoxy, carbamoylalkyl or aminosulfonyl. 
Spoj prema zahtjevu 1 ili njegova sol ili polimorf, naznačen time da R; je -C(O)-NH-Z:(Ri0); X3 je odsutan ili niži alkiliden; Z; je odsutan, -SO; ili alkil (pri čemu je alkil proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi ili karbonilalkoksi); i Rio je vodik, aril, C3-Cy cikloalkil ili heterociklil, pri čemu aril, Cg-Cy cikloalkil ili heterociklil je svaki proizvoljno supstituiran sa jednim ili više hidroksi, halogenom, alkilom (proizvoljno supstituiranim u jednom ili više položaja sa halogenom), alkoksi, karboksi, karbonilalkoksi, karbamoilalkilom ili aminosulfonilom.
Example 16. A device according to any of the preceding examples, wherein the fluid inlet (16) is connectable to a water reservoir for flushing clean water through the fluid channel (23) and out of said fluid exit (13). 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, kod kojega je ulazni otvor za fluid (16) spojen na spremnik sa čistom vodom za ispiranje, koja voda prolazi kroz kanal za fluid (23) 1 istječe iz navedenog izlaza za fluid (13).
Instability of ET 743 in aqueous solution necessitated lyophilization in order to increase the storage stability of the pharmaceutical product. 
Nestabilnost ET 743 u vodenoj otopini zahtjeva liofilizaciju u cilju povećanja stabilnosti prilikom čuvanja farmaceutskog proizvoda.
The crude product obtained solidified on drying in vacuo, resulting in 27.6 g compound 9, a yellow solid (yield 99%) which was used without further purification in the conversion to crude compound 10 described below. 
Dobiveni sirovi produkt očvrsne sušenjem u vakuumu, rezultirajući u 27,6 g spoja 9, žute krutine (iskorištenje 99 %) koji se dalje koristi bez dodatnog pročišćavanja u konverziji u sirovi spoj 10 opisan ispod.